Business Overview - Citi Trends focuses on the core African-American customer[6, 22] - The company operates approximately 590 stores with each store being around 12,000 sq ft[12, 15] - Citi Trends' sales are approximately $750 million[12] - The product margin is approximately 39% excluding one-time costs[12, 13] Recent Trends and Strategies - Citi Trends marked down approximately $26 million in unproductive inventory to create open to buy for fresh product[23] - The company is focusing on improving retail fundamentals and building foundational best practices[23, 24] - The company aims to offer branded values at 50% to 75% off MSRP[28] Path to Value Creation and Future Growth - Citi Trends is in the "Repair" phase in the second half of 2024, with plans to "Execute" in the first half of 2025, "Optimize" in the second half of 2025, and achieve "Growth" in 2026 and beyond[30] - The company aims for sales growth of approximately 4% to 6%[44] - Citi Trends is targeting square footage expansion of approximately 6% to 10%[40, 44] - The company projects EBITDA of $40 million or more[44]

Company Overview - Krispy Kreme operates in over 40 countries with approximately 2,100 shops[6] - The company sells over 1 billion doughnuts annually[6] - Doughnuts account for over 90% of sales[6] - Krispy Kreme has generated over 100 billion media impressions[8] U.S. Sales Channel - Retail accounts for 76% of U.S sales[8] - Fresh Delivery accounts for 24% of U.S sales[8] - Digital sales are part of the Retail channel[8] - U.S. household penetration is approximately 13%[8, 9] Turnaround Plan - The company expects approximately $65 million in proceeds from refranchising in Japan, which will be used for debt reduction[12] - U.S. network utilization is approximately 25%[17] - 54% of U.S. logistics have been outsourced[19]

Transaction Announcement January 12, 2026 #FD8103 #005595 #FFD105 #394B5D #38AC49 #FD8103 #394B5D Cautionary Statement Regarding Forward-Looking Statements This communication contains forward-looking statements under the safe harbor provisions of Section 21E of the Securities Exchange Act of 1934, Section 27A of the Securities Act of 1933 and the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that are not historical facts and often can be identified by th ...

Exhibit 99 Investor Presentation ICR Conference 2026 January 12, 2026 Hamilton Beach Forward-Looking Statements · Core Consumer market is North America (U.S., Canada, Mexico, Latin America) · Increasing focus of the Premium small kitchen appliance market · Growing presence in global Commercial kitchen and hotel amenities markets · Developing global Home Healthcare solutions business Hamilton Beach OTUS Powerful Brand Portfolio Best Hamilton Beach Health Hamilton Beac NUMIL Flagship brand Hamilton Beach is a ...

#005595 #FFD105 #394B5D #38AC49 #FD8103 #394B5D Transaction Announcement January 12, 2026 #FD8103 Cautionary Statement Regarding Forward-Looking Statements This communication contains forward-looking statements under the safe harbor provisions of Section 21E of the Securities Exchange Act of 1934, Section 27A of the Securities Act of 1933 and the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that are not historical facts and often can be identified by th ...

1 Forward-Looking Statements This presentation contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Cytokinetics disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Act's safe harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements, express or implied, related to Cytokinetics' research and development activities; clinical trial ini ...

Investor Presentation January 2026 Disclaimers Forward-Looking Statements This presentation includes express or implied forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this presentation, including statements regarding our strategy, future financial condition, future operations, projected costs, prospects, plans, objectives of management ...

Investor Presentation January 2026 © 2026 EyePoint. All Rights Reserved. Legal Disclaimers Various statements made in this presentation are forward-looking, within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, and are inherently subject to risks, uncertainties and potentially inaccurate assumptions. All statements that address activities, events or developments that we intend, expect, plan or believe may occur in the future, are forward-looking statements, including but not limit ...

Corporate Presentation January 2026 © 2026 ANI Pharmaceuticals, Inc. 1 Disclaimers Forward-Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Act, and Section 21E of the Securities Exchange Act of 1934, as amended. The guidance included herein is from or supplemental to the Company's press release on January 12, 2026. The Company is neither reconfirming this guidance as of the date of this investor presentation nor assuming any obligation to upd ...

IBTROZI (Taletrectinib) - IBTROZI is a next-generation ROS1 inhibitor approved for advanced ROS1+ NSCLC in the U S, Japan, and China[3] - The U S FDA approved IBTROZI on June 11, 2025[117, 120] - Since its U S launch, IBTROZI has achieved 432 new patient starts[16, 20, 120] - IBTROZI has a theoretical maximum gross market opportunity of approximately $4 billion[16] - Median Duration of Response (DOR) in TKI-naïve patients reached 50 months[24, 25] - Nuvation Bio entered an exclusive licensing agreement with Eisai for IBTROZI in Europe and additional countries, receiving up to ~$230 million in cash consideration[6] Safusidenib - Safusidenib is a potentially best-in-class mIDH1 inhibitor being evaluated in a pivotal study for high-grade and high-risk IDH1-mutant glioma[3, 4, 118, 120] - A Phase 1 study of Safusidenib in high-grade IDH1-mutant glioma showed a 17% confirmed objective response rate (cORR), including 2 complete responses (CRs)[83, 84] - A Phase 2 study of Safusidenib in low-grade IDH1-mutant glioma showed a 24-month progression-free survival (PFS) rate of 88%[71, 83, 84] Financial Status - Nuvation Bio has a robust pro forma cash balance of approximately $589 million, expected to provide a path to profitability without needing additional funding[3, 119]